The primary objective of the VBX 17-04 registry is to collect post-market safety and performance data of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX Stent Graft) in peripheral vessels in patients who require interventional treatment

Inclusion Criteria:

• Age ≥ 18 years.
• Signed informed consent form
• Endovascular indication for treatment based on treating physician's best medical judgment.
• Intend for no other stents to be placed in the same peripheral vessel(s) targeted for VBX Stent Graft placement.
• Willingness of the patient to adhere to standard of care follow-up requirements.

Exclusion Criteria:

• Known hypersensitivity to heparin or a previous incident of Heparin-Induced Thrombocytopenia (HIT) type II.
• Participation in concurrent research study or registry which may confound registry results, unless approved by Gore.
• Pregnant or breast-feeding female at time of informed consent signature.
• Life expectancy < 12 months due to comorbidities.
• Use of the VBX Stent Graft is for the treatment of de novo iliac occlusive disease.
• Use of the VBX Stent Graft is for the treatment of aortic coarctations.
• Use of the VBX Stent Graft in the coronary, pulmonary, carotid, vertebral, isolated infrarenal aortic, or vena cava vessels.

The registry has been designed with broad eligibility criteria to capture real-world VBX Stent Graft use, in multiple pathologies and in conditions needing preservation of peripheral vessels.